Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Soligenix Inc

SNGX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.40

▲ +5.01%

Market Cap $8.71M · Vol 44.56K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$8.71M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+77.80%

YoY

RSI (14)

69.54

Momentum

Beta

1.92

vs Market

52W High

$6.21

93.56% below

52W Low

$0.28

42.86% above

Volume

44.56K

Avg 48.20K

P/B

2.55

Price-to-book

ROE

N/A

Return on equity

Free Float

93.46%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Soligenix Inc (SNGX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SNGX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.01%

+8.14%

-1.43%

-63.30%

YTD

-70.15%

-86.39%

-94.41%

-99.82%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-11,080,380.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-127.32% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.55
P/FCF	N/A
EPS Growth	+77.80%
Outstanding Shares	21.77M

Technical Indicators

50-Day SMA	$0.39
200-Day SMA	$0.97
RSI (14)	69.54
Beta	1.92
52-Week High	$6.21
52-Week Low	$0.28

Volume Today	44.56K
Avg Daily Volume (30D)	48.20K
Relative Volume	0.92x
Volatility (10D)	39.41
Volatility (30D)	35.15
Free Float	93.46%

Analyst Consensus

BUY

Current Price $0.40

Mean Target $1.38

52W Low$0.28 52W High$6.21

Current

Target

$0.28 $6.21

Current Analyst target

+243.75% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SBZ0D9

ISINUS8342236044

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 7, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).